Muscle & Tissue Growth

Ligandrol (LGD-4033), also known as VK5211, is a potent, non-steroidal selective androgen receptor modulator (SARM) developed for the treatment of conditions characterized by muscle wasting and osteoporosis. As a SARM, it is designed to exert anabolic effects on skeletal muscle and bone while minimi

**Class:** SARM (Selective Androgen Receptor Modulator)

Oxandrolone (17β-hydroxy-17α-methyl-2-oxa-5α-androstan-3-one) is a synthetic oral anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). Characterized by a unique substitution of an oxygen atom for the carbon at the C-2 position in the A-ring, oxandrolone exhibits a high anabolic-

Nandrolone decanoate (ND) is a long-acting injectable ester of the anabolic-androgenic steroid (AAS) nandrolone (19-nortestosterone). Characterized by a high anabolic-to-androgenic ratio, ND has been utilized clinically for decades to treat conditions involving protein catabolism, bone density loss,

Testosterone enanthate (TE) is a long-acting esterified formulation of the primary endogenous androgen, testosterone. Since its clinical introduction in the 1950s, it has served as a cornerstone for testosterone replacement therapy (TRT) in male hypogonadism and a reference compound in clinical rese

Methenolone enanthate is a long-acting injectable anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). Characterized by a 1-methyl modification and a 2-oxo group, it exhibits a high anabolic-to-androgenic ratio and is notable for its inability to aromatize into estrogen. Origina

Stanozolol is a synthetic anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). Characterized by a high anabolic-to-androgenic ratio, it is clinically distinguished by its pyrazole ring modification and 17α-alkylation. Originally developed for the treatment of hereditary angioede

Survodutide is a dual GLP-1 and glucagon receptor agonist in clinical development by Boehringer Ingelheim for obesity and metabolic dysfunction-associated steatohepatitis (MASH). This review summarizes the clinical evidence.

Examination of GHRH, GHRP, and ghrelin mimetic mechanisms in GH secretion and IGF-1 axis research.

Selective Androgen Receptor Modulators (SARMs) are a class of therapeutic compounds with similar anabolic properties to anabolic steroids but with reduced androgenic activity. This article compares YK-11 and RAD-140 (Testolone), two of the most potent compounds currently discussed in sports pharmaco

Selective Androgen Receptor Modulators (SARMs) were developed to provide the anabolic benefits of traditional steroids—such as increased muscle mass and bone density—while minimizing androgenic side effects like prostate enlargement and hair loss. Among the most researched SARMs are Andarine (S-4) a

Cardarine (GW-501516) and Ostarine (MK-2866/Enobosarm) are two distinct chemical compounds frequently discussed in the contexts of metabolic research, sports science, and clinical muscle wasting. While they are often marketed together in the "SARM" (Selective Androgen Receptor Modulator) category, t

Oxandrolone and Nandrolone Decanoate are two of the most widely studied Anabolic-Androgenic Steroids (AAS) in clinical medicine. While both are derivatives of testosterone modified to maximize anabolic activity while minimizing androgenicity, they possess distinct biochemical profiles, routes of adm

Testosterone Enanthate (TE) and Nandrolone Decanoate (ND) represent the two most common injectable anabolic-androgenic steroids (AAS) used in clinical and performance-enhancing contexts. Testosterone Enanthate serves as the gold standard for hormone replacement therapy (HRT) and as a physiological b

Selective Androgen Receptor Modulators (SARMs) were developed to provide the therapeutic benefits of androgen replacement therapy—such as increased muscle mass and bone density—while minimizing the adverse effects associated with conventional anabolic-androgenic steroids (AAS), specifically prostate

Selective Androgen Receptor Modulators (SARMs) represent a class of therapeutic compounds designed to elicit the anabolic benefits of traditional androgenic anabolic steroids (AAS) while minimizing adverse effects on non-target tissues (e.g., prostate and sebaceous glands). Enobosarm (Ostarine/MK-28

Selective Androgen Receptor Modulators (SARMs) were developed to provide the anabolic benefits of traditional androgenic-anabolic steroids (AAS) while minimizing detrimental effects on the prostate, skin, and hair. Enobosarm (Ostarine) and Testolone (RAD-140) represent two of the most researched com

YK-11 (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester is a synthetic compound classified as a Selective Androgen Receptor Modulator (SARM). Unlike traditional non-steroidal SARMs such as Ostarine or Ligandrol, YK-11 possesses a steroidal

Testolone (RAD-140) is a potent, non-steroidal selective androgen receptor modulator (SARM) originally developed by Radius Health, Inc. It was designed to overcome the limitations of conventional androgen therapy, such as prostate enlargement and virilization, by exhibiting high tissue selectivity.

Andarine (also known as S-4 or GTx-007) is an early-generation, nonsteroidal selective androgen receptor modulator (SARM) belonging to the aryl propionamide class. Developed initially for the treatment of conditions such as muscle wasting and osteoporosis, Andarine demonstrates high affinity for the

Drostanolone propionate (2α-methyl-5α-androstan-17β-ol-3-one propionate) is a synthetic anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). Originally developed for the treatment of advanced breast cancer in postmenopausal women, it is characterized by its inability to aromatiz

Boldenone undecylenate, a synthetic derivative of testosterone originally developed for veterinary use, is a long-acting injectable anabolic-androgenic steroid (AAS). Characterized by a double bond between the C1 and C2 positions, the compound exhibits a favorable ratio of anabolic to androgenic act

Trenbolone acetate (TBA) is a potent synthetic 19-nortestosterone derivative classified as an anabolic-androgenic steroid (AAS). Originally developed for veterinary applications—specifically to increase muscle mass and feed efficiency in beef cattle—TBA has become a focal point of pharmacological in

Evidence-based review of GH secretagogue peptide synergy, examining pulsatile GH release, receptor mechanisms, and combination protocols.